← Back to patent-cliff list
Zuranolone
Tier C — Watch / tradeZuranolone
Sage Therapeutics Inc
Originator
2023
First approval
-
Expiry (public)
$0.2B ▲
Peak sales
Small molecule
Type
Targets：GABAAR
Brand：Zurzuvae
Indications (approved)：产后抑郁症, Depressive disorder
Regional status
US
Approved
2023-08-04
EU
Approved
2025-09-17
China
-
Japan
Approved
2025-12-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zuranolone?
Approved indications include: 产后抑郁症, Depressive disorder.
When does the Zuranolone patent expire?
No public expiry year is available for Zuranolone yet; this page updates once verified.
How do I get a quote for Zuranolone intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27